Martin Luther University of Halle-Wittenberg, also referred to as MLU, is a public, research-oriented university in the cities of Halle and Wittenberg and the largest and oldest university in the German State of Saxony-Anhalt.

During the past decade, Martin-Luther-Universität Halle-Wittenberg conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 6 clinical trials were completed, i.e. on average, 54.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 5 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Martin-Luther-Universität Halle-Wittenberg" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 8 trials, followed by "Martin-Luther-Universität Halle-Wittenberg" with 5 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "AGO Study Group" with 3 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Martin-Luther-Universität Halle-Wittenberg" #1 collaborator was "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials as a collaborator, "NCIC Clinical Trials Group" with 2 trials as a collaborator, "National Cancer Institute (NCI)" with 2 trials as a collaborator, "2ConduCT" with 1 trials as a collaborator and "AMS Advanced Medical Services GmbH" with 1 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Martin-Luther-Universität Halle-Wittenberg" are "Breast Cancer" (3 trials), "Colorectal Cancer" (3 trials), "Dementia" (2 trials), "Leukemia" (2 trials) and "Metastatic Colorectal Cancer" (2 trials). Many other conditions were trialed in "Martin-Luther-Universität Halle-Wittenberg" in a lesser frequency.

Most popular intervention types in "Martin-Luther-Universität Halle-Wittenberg" are "Drug" (39 trials), "Other" (6 trials), "Procedure" (6 trials), "Biological" (4 trials) and "Device" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "cisplatin" (6 trials), "carboplatin" (3 trials), "etoposide" (3 trials) and "radiation therapy" (3 trials). Other intervention names were less common.

The vast majority of trials in "Martin-Luther-Universität Halle-Wittenberg" are 45 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Martin-Luther-Universität Halle-Wittenberg". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 36 completed trials in Martin-Luther-Universität Halle-Wittenberg, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Martin-Luther-Universität Halle-Wittenberg, 2 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".

Martin-Luther-Universität Halle-Wittenberg has several departments that took part in Clinical trials: "Universitätsklinikum Halle (Saale) / Universitätsklinik und Poliklinik für Innere Medizin, Schwerpunkt Pneumologie" - 8 trials, "Department of Neurology, University of Halle-Wittenberg" - 5 trials, "Universitaetsklinik und Poliklinik fuer Dermatologie und Venerologie" - 4 trials, "Maternity Clinic/Perinatal Treatment Center, Halle university hospital, Martin-Luther-Universität Halle-Wittenberg" - 4 trials, "Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie" - 6 trials, "Universitätsklinikum Halle, Klinik für Innere Medizin IV" - 2 trials